

Electronic Acknowledgement Receipt

EFS ID:	1353492
Application Number:	10789835
International Application Number:	
Confirmation Number:	8254
Title of Invention:	Chroman-derived anti-androgens for treatment of androgen-mediated disorders
First Named Inventor/Applicant Name:	Todd A. Thompson
Customer Number:	31096
Filer:	Colin Lee Fairman
Filer Authorized By:	
Attorney Docket Number:	054030-0052
Receipt Date:	05-DEC-2006
Filing Date:	27-FEB-2004
Time Stamp:	16:38:55
Application Type:	Utility

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1		Restriction_Response.pdf	145989	yes	14

Multipart Description/PDF files in .zip description			
Document Description	Start	End	
Response to Election / Restriction Filed	1	1	
Claims	2	9	
Applicant Arguments/Remarks Made in an Amendment	10	14	

Warnings:

Information:

Total Files Size (in bytes):	145989
------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.